medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2023, Number 2

<< Back Next >>

Rev Biomed 2023; 34 (2)

Epidemiological and clinical predictors of COVID-19 in presymptomatic and symptomatic outpatients. A single-center cohort

García-González I, Mendoza-Oliveros T, Reyes Canché-Pech J, Chin-Hau L, Gómez-García AJ, López-Díaz RI, Sauri-Medina NE, Ceballos-López AA, López-Novelo ME

Language: Spanish
References: 30
Page: 158-167
PDF size: 162.14 Kb.


ABSTRACT

Background. In Mexico, the epidemiology of SARS-CoV-2 infection in the ambulatory setting and the identification of COVID-19 predictors have been poorly studied.
Objective. To describe the epidemiological and clinical characteristics of presymptomatic and symptomatic outpatients with SARS-CoV-2 and its association with infection.
Material and Methods. Retrospective cohort of 9 598 outpatients from Yucatan who requested molecular diagnosis of SARS-COV-2 during 2020. All patients answered a questionnaire to record epidemiological and clinical variables. Predictors of positivity to infection were identified by multivariable logistic regression.
Results. The incidence of SARS-CoV-2 was 28.8%. Of the total number of positive patients, 66.1% had previous contact with COVID-19 patients, 65.0% had symptoms and 35.0% were presymptomatic at the time of sampling. The most frequent comorbidity in the positive patients was arterial hypertension (25.2%, p=0.005). In general, male sex, age, previous contact with COVID-19 cases, arterial hypertension, and the concomitant symptoms of dry cough/sore throat and anosmia/ageusia were independently associated with SARS-CoV-2. Previous contact with COVID-19 cases was a strong predictor of positivity in presymptomatic carriers.
Conclusions. The identification of non-invasive risk predictors of SARS-CoV-2 can be used for epidemiological surveillance of COVID-19 in an ambulatory setting. This is the first study on SARS-CoV-2 predictors in resident population from Yucatan.


REFERENCES

  1. SSA/SPPS/DGE/DIE/InDRE/UIES. [Internet]. Informetécnico diario COVID-19 México 31/12/2021. México:Secretaría de Salud [Consultado 10 Junio 2022].Disponible en: https://www.gob.mx/cms/uploads/attachment/file/689279/Comunicado_Tecnico_Diario_COVID-19_2021.12.27_1_.pdf.

  2. Comunicado de prensa de la Secretaría de Salud deYucatán. [Consultado 22 Agosto 2022]. Disponible en:https://www.yucatan.gob.mx/saladeprensa/ver_nota.php?id=5687

  3. Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, LeeVJ. Presymptomatic transmission of SARS-CoV-2-Singapore, January 23-March 16, 2020. MMWRMorb Mortal Wkly Rep. 2020;69(14):411-415. http://www.10.15585/mmwr.mm6914e1

  4. Buitrago-Garcia D, Egli-Gany D, Counotte MJ,Hossmann S, Imeri H, Ipekci AM, et al. Occurrenceand transmission potential of asymptomatic andpresymptomatic SARS-CoV-2 infections: a livingsystematic review and meta-analysis. PLoS Med2020;17(9):1-25. http://dx.doi.org/10.1371/journal.pmed.1003346

  5. Sun Y, Koh V, Marimuthu K, Ng OT, Young B, VasooS, et al. Epidemiological and Clinical Predictors ofCOVID-19. Clin Infect Dis. 2020;28;71(15):786-92.https://doi.org/10.1093/cid/ciaa322.

  6. Wynants L, Calster BV, Collins GS, Riley RD, HeinzeG, Schuit E, et al. Prediction models for diagnosisand prognosis of covid-19: systematic review andcritical appraisal. BMJ. 2020;7;369:m1328. https://doi.org/10.1136/bmj.m1328.

  7. Menni C, Valdes AM, Freidin MB, Sudre CH, NguyenLH, Drew DA, et al. Real-time tracking of selfreportedsymptoms to predict potential COVID-19. Nat Med.2020;26(7):1037-40. https://doi.org/10.1038/s41591-020-0916-2.

  8. Fernández-Rojas MA, Ruiz Esparza L, Campos-RomeroA, Calva-Espinosa DY, Moreno-Camacho JL, Langle-Martínez AP, et al. Epidemiology of COVID-19 inMexico: Symptomatic profiles and presymptomaticpeople. Internat J Infec Dis 2021;104:572-579. https://doi.org/10.1016/j.ijid.2020.12.086

  9. Dirección General de Epidemiología. [Internet].Lineamiento estandarizado para la vigilanciaepidemiológica y por laboratorio de COVID19. Agostode 2020. México: Secretaria de Salud [Ciado 12 Sep2021]. Disponible en: https://coronavirus.gob.mx/wpcontent/uploads/2020/09/Lineamiento_VE_y_Lab_Enf_Viral_Ago-2020.pdf.

  10. Organización Mundial de la Salud. [Internet]. WHOreference number: WHO/2019-nCoV/Surveillance_Case_Definition 2020 [Citado 12 Sep 2021]Disponible en: https://apps.who.int/iris/bitstream/handle/10665/336482/WHO-2019-nCoV-Surveillance_Case_Definition-2020.1-spa.pdf.

  11. Dirección General de Epidemiologia. [Internet]. DatosAbiertos bases Históricas Abril-Diciembre 2020.México: Secretaría de Salud. [Citado 21 Oct 2021].Disponible en: https://www.gob.mx/salud/documentos/datos-abiertos-bases-historicas-direccion-general-deepidemiologia.

  12. Corman VM, Landt O, Kalser M, Molekamp R, MeijerA, Chu DKW, et al. Detection of 2019 novel coronavirus(2019-nCoV) real time RT-PCR. Euro Surveill.2020;25(3):pi=2000045. https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045.

  13. CDC 2019-Novel Coronavirus (2019-nCoV). [Internet].Real-Time RT-PCR Panel. 2020 [Citado 21 Sep 2021].Disponible en: https://www.fda.gov/media/134922/download.

  14. Martínez SJ, A. Vargas F. [Internet]. Covid-19: evolución yestimaciones de las curvas epidémicas, Temas estratégicosNo. 78, 2020. Senado de la República, México. [Citado 30Sep 2021]. Disponible en: http://bibliodigitalibd.senado.gob.mx/bitstream/handle/123456789/4877/Reporte%20TE%2078%20Curvas%20epidemicas%20F.pdf?sequence=1&isAllowed=y.

  15. Oran DP, Topol EJ. The Proportion of SARS-CoV-2Infections That Are Asymptomatic: A SystematicReview. Ann Intern Med 2021;174:655. https://doi:10.7326/M20-6976.

  16. Kammar-García, Vidal-Mayo J, Vera-Zertuche JM,Lazcano Hernández M, Vera-López O, Segura-BadillaO, et al. Impact of Comorbidities in Mexican SARSCoV-2-Positive Patients: A retrospective analysis in anational cohort. Rev Invest Clin. 2020;72(3):151-158.https://doi.org/10.24875/ric.20000207.

  17. Ortolan A, Lorenzin M, Felicetti M, Doria A, RamondaR. Does gender influence clinical expression and diseaseoutcomes in COVID-19? A systematic review and metaanalysis.Interna J Infec Dis 2020;99:496-504. https://doi.org/10.1016/j.ijid.2020.07.076

  18. Abate BB, Kassie AM, Kassaw MW, Aragie TG,Masresha SA. Sex difference in coronavirus disease(COVID-19): a systematic review and meta-analysis.BMJ Open. 2020;10(10):e040129. https://doi:10.1136/bmjopen-2020-040129.

  19. Conti P, Younes A. Coronavirus COV-19/SARS-CoV-2affects women less than men: clinical response to viralinfection. J Biol Regul Homeost Agents. 2020;34(2):339-343. https://doi:10.23812/Editorial-Conti-3.

  20. Salah HM, Mehta JL. Hypothesis: sex-relateddifferences in ACE2 activity may contribute to highermortality in men versus women with COVID-19. JCardiovasc Pharmacol Ther 2021;26(2):114-118. https://doi:10.1177/1074248420967792.

  21. Griffith DM, Sharma G, Holliday CS, Enyia OK,Valliere M, Semlow AR, et al. Men and COVID-19:A Biopsychosocial Approach to Understanding SexDifferences in Mortality and Recommendations forPractice and Policy Interventions. Prev ChronicDis 2020;17:200247. http://dx.doi.org/10.5888/pcd17.200247

  22. Denova-Gutiérrez E, Lopez-Gatell H, Alomia-ZegarraJL, López-Ridau-ra R, Zaragoza-Jimenez CA, et al. TheAssociation of obesity, type 2 diabetes, and hypertensionwith severe coronavirus disease 2019 on admissionamong Mexican patients. Obesity. 2020;28(10):1826-32.https://doi.org/10.1002/oby.22946

  23. DataMÉXICO. Mérida. [Internet]. Secretaria deEconomía 2021. (Fecha de acceso 07-09-2021). [Citado5 Marzo 2021]. Disponible en: https://datamexico.org/es/profile/geo/merida?comorbilityOption=positiveOption

  24. Lechien JR, Chiesa-Estomba CM, De Siati DR, HoroiM, Le Bon SD, Rodríguez A, et al. Olfactory andgustatory dysfunctions as a clinical presentation ofmild-to-moderate forms of the coronavirus disease(COVID-19): a multicenter European study. Eur ArchOtorhinolaryngol. 2020;277(8):2251-2261. https://doi:10.1007/s00405-020-05965-1.

  25. Chen MY, Hsih WH, Ho MW, Lai YCh, Liao WCh,Chen ChY, et al. Younger adults with mild-to-moderateCOVID-19 exhibited more prevalent olfactorydysfunction in Taiwan. Journal of Microbiology,Immunology and Infection 2021;54:794e800795. https://doi.org/10.1016/j.jmii.2021.01.006.

  26. Borsetto D, Hopkins C, Philips V, Obholzer R, TirelliG, Polesel J, et al. Self-reported alteration of sense ofsmell or taste in patients with COVID-19: a systematicreview and meta-analysis on 3563 patients. Rhinology.2020;58(5):430-6. https://doi.org/10.4193/Rhin20.185

  27. Brandal LT, MacDonald E, Veneti L, Ravlo T, Lange H,Naseer U, et al. Outbreak caused by the SARS-CoV-2Omicron variant in Norway, November to December2021. Eurosurveillance. 2021 26:2101147. https://doi:10.2807/1560-7917.ES.2021.26.50.2101147

  28. Boscolo-Rizzo P, Tirelli G, Meloni P, Hopkins C,Madeddu G, De Vito A, et al. COVID-19-related smelland taste impairment with widespread diffusion of SARSCoV-2 Omicron variant. Int Forum Allergy Rhinol.2022;1-9 https://doi:10.1101/2022.02.17.22271116

  29. Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinicalcharacteristics of 24 asymptomatic infections withCOVID-19 screened among close contacts in Nanjing,China. Sci China Life Sci. 2020;63(5):706-11. https://doi.org/10.1007/s11427-020-1661-4.

  30. Tindale LC, Stockdale JE, Coombe M, Garlock ES,Lau WYV, Saraswat M, et al. Evidence for transmissionof COVID-19 prior to symptom onset. Elife.2020;22;9:e57149. http://doi:10.7554/eLife.57149.




2020     |     www.medigraphic.com